Medical Care Technologies Inc. (OTC PINK:MDCE) Slashes Outstanding Share Count by 680,000,000 Shares

September 8, 2025 9:11 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) (the "Company" or "MDCE") today announced that Chief Executive Officer Marshall Perkins has voluntarily surrendered 680,000,000 shares of common stock back to the Company's treasury. This action reduces the total number of outstanding shares by 680,000,000. This a major material event to improve MDCE's share structure and will be filed and disclosed with OTC Markets in the coming days.This decisive...

Read more

CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study

September 8, 2025 9:00 AM

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that the Safety Monitoring Committee (SMC) has completed its review of cohort 4 (600 mg target dose) along with its continued assessment of the first three cohorts of the company's Phase 1 dose-escalating and safety study of CID-103 in...

Read more

From Telehealth to Trust: Flash Survey of WHX Attendees on the Next Wave of Middle East Digital Health Startups

September 8, 2025 8:45 AM

Black Book Research has released results from a flash survey of 50 attendees at WHX Tech Dubai, capturing how digital health startups are reshaping care delivery in the Middle East. The survey reveals strong momentum for telehealth platforms and patient engagement solutions, with respondents stressing that compliance, consent, and privacy are the deciding factors for adoption.WHX Tech 2025, held at the Dubai World Trade Centre, welcomed more...

Read more

CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market

September 8, 2025 8:35 AM

CS Diagnostics Corp. (OTCQB:CSDX) is delighted to announce the submission of its CS-Protect Hydrogel patenting process application as a supporting milestone for its application at the U.S. Food and Drug Administration (FDA). The company has partnered with Paul & Albrecht Patentanwälte PartG mbB, a renowned German intellectual property law firm founded in 1977.Paul & Albrecht Patentanwälte https://paul-albrecht.com/en/ is recognized for its...

Read more

Senzime to Present at the European Growth Virtual Investor Conference on September 11

September 8, 2025 7:30 AM

Senzime AB (STO:SEZI)(Nasdaq Stockholm:SEZI)(US OTCQX:SNZZF), a leader in precision-based monitoring of patients undergoing anesthesia, today announced that Philip Siberg, CEO of Senzime, has been selected to present at the European Growth Virtual Investor Conference on September 11, 2025.Date: September 11, 2025Time: 10:00 a.m. ET / 16:00 CETLink:Conference Registration & Access (see also link below)This will be a live, interactive online event...

Read more

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

September 8, 2025 7:30 AM

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that the SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi (CCAD). Earlier this year, in May 2025, SKNJCT-004 received "study...

Read more

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

September 8, 2025 7:00 AM

Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a late clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, has launched its registrational Phase 3 trial of eRapa - its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP), a debilitating disease of the lower GI tract. This post was written and...

Read more

DEA National Marijuana Embarrassment: DEA Forces VA to Import Cannabis After Blocking MMJ BioPharma Cultivation US Supply

September 8, 2025 5:00 AM

In a stunning regulatory paradox, the U.S. Department of Veterans Affairs (VA) has applied for DEA approval to import marijuana extracts from abroad to study PTSD and chronic pain in veterans. While this step may help veterans, it underscores a catastrophic policy failure: the DEA has systematically blocked American companies from producing the very same research materials, forcing the federal government itself to look overseas. This is not...

Read more

Positive Study Results with TrkA-NAM ACD137 Against Knee Osteoarthritis Presented at Pain Conference NeuPSIG 2025

September 8, 2025 4:20 AM

AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its presentation at the international pain conference NeuPSIG 2025 is now available on the company's website. It includes data from preclinical studies with ACD137, the company's drug candidate in knee osteoarthritis-related pain."These positive...

Read more

Monthly Update - August: Continued Growth, Strong Interest, and Preparations for a Busy Fall

September 8, 2025 3:35 AM

iZafe Group (STO:IZAFE-B) - August is typically a calmer month, but we're seeing continued positive momentum. The number of billable Dosell units increased by 6% compared to July, giving us a stable foundation heading into the fall. The largest growth came from the Netherlands with an 8% increase, but other markets are also showing strength. This is yet another clear sign that our solution is not only in demand - but increasingly used.Continued...

Read more

Hemogenyx Pharmaceuticals PLC Announces Manufacturing Partnership with Made Scientific

September 8, 2025 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce a manufacturing partnership with Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), to advance HG-CT-1, the Company's autologous Chimeric Antigen Receptor T-cell (CAR-T) therapy for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.Under the agreement, Hemogenyx Pharmaceuticals will leverage...

Read more

Housing Stabilization Providers Report Impact Following Payment Suspensions

September 6, 2025 10:45 PM

On August 1, 2025, the Minnesota Department of Human Services (DHS) suspended Medicaid payments to 77 Housing Stabilization Service providers. According to DHS investigator Ashley Stoupe, the suspensions were issued with no specified end date, creating uncertainty for providers and clients statewide.Twyla Martin ImageProviders state that the suspensions followed data-mining reviews described as investigations. While the reviews functioned as...

Read more

WHX Tech Dubai 2025 Opens as Global Digital Health Marketplace Connecting Innovators With Middle East Leaders

September 6, 2025 9:00 AM

As WHX Tech Dubai 2025 opens today, more than 5,000 healthcare leaders from around the world are converging to explore how global digital health innovators can partner with Middle East providers, payers, and regulators. This year's program, held September 8-10 in partnership with HIMSS, highlights the region's growing demand for smart hospital transformation and population health innovations.Independent benchmarking firm Black Book Research...

Read more

The Global PAD Association has presented the 2025 Walking As Therapy Breakthrough Research of the Year award to The STRIDE Trial Research Team led by Dr. Marc P. Bonaca

September 5, 2025 5:00 PM

The Global PAD Association has presented the 2025 Walking As Therapy Breakthrough Research of the Year award to The STRIDE Trial Research Team led by Dr. Marc P. Bonaca, Executive Director at CPC Clinical Research, for pioneering research demonstrating significant improvements in walking capacity, symptoms, and quality of life for peripheral artery disease patients through innovative therapeutic intervention. The STRIDE trial represents a...

Read more

MEDvidi Launches AI-Powered Healthcare Solutions to Transform Telemedicine

September 5, 2025 1:15 PM

MEDvidi, a platform for delivering remote, personalized mental health treatment, is launching AI-powered healthcare solutions for telemedicine platforms. The new artificial intelligence tools from MEDvidi aim to redefine standards in clinical efficiency, compliance, and patient experience.The medical field may face a 21,000-psychiatrist gap by 2030, and currently, specialists are bound to spend excessive time on administrative tasks. In light of...

Read more

Angle PLC Announces Notice of Results

September 5, 2025 10:30 AM

ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, will be releasing its interim results for the six months ended 30 June 2025 on Tuesday 9 September 2025.A meeting for analysts will be held at 11:00 am BST on Tuesday 9 September 2025. In light of the planned tube strikes this will be held...

Read more

Justera Health Announces Auditor Change

September 5, 2025 10:25 AM

Justera Health Ltd. (CSE:VTAL)(OTC:SCRSF) ("Justera" or the "Company") announces it has changed its auditors form SHIM & Associates LLP ("Former Auditor") to Horizon Assurance LLP ("Successor Auditor") effective August 7, 2025. The Former Auditor resigned as the Company's auditor effective as of June 2, 2025. The Company's Board of Directors has appointed the Successor Auditor as the new auditor until the next Annual General Meeting of...

Read more

Medical Care Technologies Inc. (OTC PINK:MDCE) Unveils AI Age-Based Health Risk Estimator Targeting $1 Trillion Digital Health Market by 2030

September 5, 2025 9:30 AM

Medical Care Technologies Inc. (OTC PINK:MDCE) today unveiled its AI Facial Age-Based Health Risk Estimator, a breakthrough technology that uses facial imaging to deliver predictive health insights.The system leverages micro-wrinkle density, skin elasticity, and tonal gradient analysis to generate real-time estimates of biological age and chronic disease predisposition. By combining facial biometrics with predictive AI health markers, MDCE aims...

Read more

Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board

September 5, 2025 9:00 AM

Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. John Mackey, Professor Emeritus in the Department of Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. His expertise will support Onco's efforts in aligning translational research with clinical execution, particularly as the Company progresses toward later-stage development...

Read more

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

September 5, 2025 9:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference, which takes place September 8-10, 2025.Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 27th Annual Global Investment ConferenceWhen: On-demand virtual presentation available starting at 7:00 AM Eastern on Friday,...

Read more